Trial Review

Please note that the ANZCTR will be unattended on Monday 9th June due to an Australian public holiday.

Reset your password and enable multi-factor authentication (MFA)


For ANZCTR account holders: to help ensure the cyber safety of your account, you’ll need to reset your password and set-up multi-factor authentication (MFA) as per the instructions below.


  1. Go to the Login page, click ‘reset password’ and follow the instructions.
  2. Check your email for the link to set a new password.
  3. Create a new password that meets requirements.
  4. Return to the Login page and enter your new password. A verification code will be sent to your email.
  5. Check your email for the code and enter it on the Login page. If the code is entered incorrectly, you can re-enter the correct one or request a new one.

Learn more about MFA and its importance on the Australian Signals Directorate website.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT00895947




Registration number
NCT00895947
Ethics application status
Date submitted
6/05/2009
Date registered
8/05/2009
Date last updated
16/09/2011

Titles & IDs
Public title
Interferon Alpha Lozenges in the Prevention of Winter Colds and Flu
Scientific title
Evaluation of Natural Human Interferon Alpha Lozenges in the Prevention of Winter Colds and Flu in Perth, Western Australia
Secondary ID [1] 0 0
2008-113
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Upper Respiratory Tract Infections 0 0
Condition category
Condition code
Respiratory 0 0 0 0
Other respiratory disorders / diseases
Infection 0 0 0 0
Other infectious diseases
Infection 0 0 0 0
Studies of infection and infectious agents

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - interferon-alpha
Other interventions - placebo

Experimental: Interferon-alpha - 150 international units of interferon-alpha

Placebo comparator: placebo - placebo lozenges


Treatment: Drugs: interferon-alpha
a lozenge for oral dissolution containing 150 international units of human interferon-alpha taken once daily for 16 weeks

Other interventions: placebo
placebo lozenges for oral dissolution taken once daily for 16 weeks
Intervention code [1] 0 0
Treatment: Drugs
Intervention code [2] 0 0
Other interventions
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Frequency of Influenza-like Illness
Assessment method [1] 0 0
Number of subjects in each group meeting the definition of influenza-like illness during treatment (i.e. those subject reporting one or more moderate to severe cold/flu symptoms during the treatment period).
Timepoint [1] 0 0
16 weeks
Secondary outcome [1] 0 0
Symptom Incidence/Severity
Assessment method [1] 0 0
Number of subjects in each group reporting 13 different cold/flu symptoms assessed weekly
Timepoint [1] 0 0
16 weeks
Secondary outcome [2] 0 0
Impact of Cold/Flu Symptoms
Assessment method [2] 0 0
Number of subjects in each group reporting that cold/flu symptoms impacted the following 9 measures of daily life: ability to (1) think clearly, (2) sleep well, (3) breathe easily, (4) walk, climb stairs and exercise, (5) perform daily tasks, (6) work outside the home, (7) work inside the home, (8) interact with others, and (9) live personal life.
Timepoint [2] 0 0
16 weeks
Secondary outcome [3] 0 0
Negative Events Related to Cold/Flu Symptoms
Assessment method [3] 0 0
Number of subjects in each group reporting one or days of occurrence of the following 6 negative events: (1) felt sick, (2) missed work, (3) went to the doctor, (4) went to the pharmacy, (5) took cold/flu medication, and (6) skipped a planned activity
Timepoint [3] 0 0
16 weeks
Secondary outcome [4] 0 0
Incidence/Severity of Viral Respiratory Infections
Assessment method [4] 0 0
Number of subjects in each group with a confirmed viral respiratory infection and the proportion of subjects reporting a mild vs. moderate to severe infection
Timepoint [4] 0 0
16 weeks

Eligibility
Key inclusion criteria
* Male or non-pregnant female
* Females of child-bearing potential must practice a medically accepted form of birth control
Minimum age
18 Years
Maximum age
75 Years
Sex
Both males and females
Can healthy volunteers participate?
Yes
Key exclusion criteria
* Currently exhibiting an acute upper respiratory tract infection
* history of chronic respiratory disease requiring regular therapy(i.e. COPD, asthma, bronchitis, etc.)
* any condition likely to increase the risk of severe or complicated influenza (i.e. cardiac disease, chronic renal disease, endocrine diseases, including diabetes and/or immunosuppressive therapy)
* any condition requiring regular treatment with antihistamines, analgesics or antipyretics
* known infection with HIV, hepatitis B virus or hepatitis C virus
* any other serious, uncontrolled disease
* any active infections requiring use of antibiotic or antiviral drugs
* non-ambulatory status
* suspected drug or alcohol abuse

Study design
Purpose of the study
Prevention
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/04/2009
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
1/03/2010
Sample size
Target
Accrual to date
Final
200
Recruitment in Australia
Recruitment state(s)
WA
Recruitment hospital [1] 0 0
University of Western Australia - Nedlands
Recruitment postcode(s) [1] 0 0
6009 - Nedlands

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Ainos, Inc. (f/k/a Amarillo Biosciences Inc.
Country
Other collaborator category [1] 0 0
Other
Name [1] 0 0
Department of Health, Western Australia
Country [1] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Public notes

Contacts
Principal investigator
Name 0 0
David Smith, PhD
Address 0 0
Path West Laboratory Medicine WA
Country 0 0
Phone 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Email 0 0
Contact person for scientific queries

No information has been provided regarding IPD availability


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

No documents have been uploaded by study researchers.

Results are available at https://clinicaltrials.gov/study/NCT00895947